Get started
Author

Anne Jacquet-Bescond

Observed names: A Jacquet-Bescond, A. Jacquet-Bescond
OpenAlex ID: A5005779956
S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
2013 · Mike F. Burbridge, Céline J. Bossard, et al. · Molecular Cancer Therapeutics · 93
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models
2016 · Federica Guffanti, Rosaria Chilà, et al. · Neoplasia · 40
PDF
Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms
2013 · A Ali, O Bluteau, et al. · Cell Death and Disease · 40
PDF
Treatment of Nasopharyngeal Carcinoma Cells with the Histone-Deacetylase Inhibitor Abexinostat: Cooperative Effects with Cis-platin and Radiotherapy on Patient-Derived Xenografts
2014 · Mélanie Gressette, Benjamin Vérillaud, et al. · PLoS ONE · 37
PDF
Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I
2013 · Sylvain Fouliard, Renata Robert, et al. · European Journal of Cancer · 33
The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy
2017 · Céline Clémenson, Cyrus Chargari, et al. · Molecular Cancer Therapeutics · 32
Application of Hematological Toxicity Modeling in Clinical Development of Abexinostat (S-78454, PCI-24781), A New Histone Deacetylase Inhibitor
2013 · Quentin Chalret du Rieu, Sylvain Fouliard, et al. · Pharmaceutical Research · 10
301 First-in-human phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors
2015 · A. Azaro, J. Rodon, et al. · European Journal of Cancer · 4
125O First-in-human study of oral S 49076, a MET/AXL/FGFR inhibitor, in advanced solid tumors
2015 · S. Postel-Vinay, A. Hollebecque, et al. · Annals of Oncology · 2
Abstract A238: S 49076, a novel, potent, MET/FGFR/AXL kinase inhibitor with wide antitumor activity.
2011 · Mike F. Burbridge, Carine Saunier, et al. · Molecular Cancer Therapeutics · 2
340 Preclinical activity of the VEGFR, FGFR and PDGFR inhibitor lucitanib in FGFR2 aberrant endometrial and gastric cancer models
2014 · F. Guffanti, R. Chila, et al. · European Journal of Cancer · 1
Abstract A240: Preclinical molecular stratification of human tumors sensitive or resistant to S 49076, a novel MET/FGFR/AXL kinase inhibitor.
2011 · Mike F. Burbridge, Celine Bossard, et al. · Molecular Cancer Therapeutics · 1
Supplementary Figure S2 from S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
2023 · Mike F. Burbridge, Céline J. Bossard, et al.
Supplementary Figure S3 from S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
2023 · Mike F. Burbridge, Céline J. Bossard, et al.
Supplementary Figure Legends from S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
2023 · Mike F. Burbridge, Céline J. Bossard, et al.
PDF
Supplementary Figure S1 from S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
2023 · Mike F. Burbridge, Céline J. Bossard, et al.
Supplementary Table S1 from S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
2023 · Mike F. Burbridge, Céline J. Bossard, et al.
Data from S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
2023 · Mike F. Burbridge, Céline J. Bossard, et al.
Supplementary Figure S5 from The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy
2023 · Céline Clémenson, Cyrus Chargari, et al.
Supplementary information from The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy
2023 · Céline Clémenson, Cyrus Chargari, et al.
Supplementary Figure S6 from The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy
2023 · Céline Clémenson, Cyrus Chargari, et al.
Supplementary Figure S4 from The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy
2023 · Céline Clémenson, Cyrus Chargari, et al.
Supplementary Figure S1 from The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy
2023 · Céline Clémenson, Cyrus Chargari, et al.
Supplementary Table S1 from The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy
2023 · Céline Clémenson, Cyrus Chargari, et al.
Supplementary Figure S3 from The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy
2023 · Céline Clémenson, Cyrus Chargari, et al.
Works count: 48
Citation count: 295
H-index: 7
I10-index: 7
Year
Topic
Type